Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084116 | 0.83 | CNR1 (0.48) | KDM4EALDH1A1HPGDSMN1; SMN2CNR1 | |
| SCHEMBL10989518 | 0.79 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDLMNAL3MBTL1 | |
| SCHEMBL822678 | 0.78 | PTGER1 (0.56) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL11516631 | 0.78 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL9725937 | 0.77 | HPGD (0.50) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL8119176 | 0.76 | BCHE (0.51) | KDM4EALDH1A1HPGDSMN1; SMN2GAA | |
| SCHEMBL23105448 | 0.74 | CNR1 (0.48) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL7267265 | 0.74 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL23105432 | 0.74 | FAAH (0.50) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL4080155 | 0.73 | CNR1 (0.65) | KDM4EALDH1A1HPGDHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7057051-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | disclosed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | disclosed |
| WO-2003007887-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | KDM4E 1781/4885ALDH1A1 3232/4885HPGD 3177/4885 |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | KDM4E 1781/4885ALDH1A1 3232/4885HPGD 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.